Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Rapid, efficient and durable fetal hemoglobin production following CS-101 treatment in transfusion-dependent β-thalassemia participants: An autologous, ex vivo edited CD34+ stem cell product using the innovative transformer base editor (tBE)

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJia ChenYLYongrong LaiXQXiaowen Qian

Discussion

Loading...

Member takes

Overview

Clinical trial demonstrates improved fetal hemoglobin levels in β-thalassemia patients, indicating potential for treatment of hemoglobinopathies.

Key Points

  • Fetal hemoglobin levels increased significantly in β-thalassemia patients after CS-101 treatment, highlighting its promising efficacy.
  • Median follow-up reached 12.7 months, showing sustained transfusion independence in participants post-infusion.
  • Analysis of clinical outcomes reports safety measures, with adverse events primarily stemming from conditioning regimen.
  • Results support CS-101 as a pioneering gene editing therapy for β-thalassemia, with potential for wide application in hemoglobin disorders.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e17bhttps://doi.org/10.1182/blood-2025-6090
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease: Safety and efficacy findings from the ongoing BEACON study2025 · 2 citations
  2. 2All 19 subjects with transfusion-dependent β-thalassemia achieved transfusion independence after treatment with RM-001 (autologous HBG1/2 promoter-modified CD34+ hematopoietic stem and progenitor cells)2025
  3. 3Real-world experience with apheresis for gene therapy in transfusion-dependent β-thalassemia: The largest single-center report2025
  4. 4Targeted disruption of BCL11A ZnF4 enhances fetal hemoglobin in β-thalassemia and sickle cell disease: A druggable approach2025
  5. 5Evaluating the efficacy and safety of gene therapy in transfusion-dependent β-thalassemia: A focus on hemolysis improvement and clonal hematopoiesis monitoring2025 · 1 citations